Domov › Rak jeter (hepatocelularni karcinom) › New York › New York City
Klinične študije za Rak jeter (hepatocelularni karcinom) v New York City, NY
24 študij za Rak jeter (hepatocelularni karcinom) išče udeležence na lokacijah v New York City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study of ZW251 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Vključevanje udeležencevFaza 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Vključevanje udeležencevFaza 1/2
- Research Facility, New York
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Vključevanje udeležencevFaza 1
- Columbia University Irving Medical Center, New York
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Vključevanje udeležencevOpazovalna študija
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- in še 1
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Vključevanje udeležencevFaza 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Vključevanje udeležencevFaza 1
- New York Cancer & Blood Specialists, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Vključevanje udeležencevFaza 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Vključevanje udeležencevFaza 3
- Mount Sinai Hospital, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Vključevanje udeležencevFaza 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Vključevanje udeležencevFaza 4
- Icahn School of Medicine at Mount Sinai, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Vključevanje udeležencevFaza 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Vključevanje udeležencevFaza 1
- Clinical Trial Site, New York
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Vključevanje udeležencev
- VA NY Harbor Healthcare System, New York, NY, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- USA04-0, New York
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center - New York, New York
HOPE Against Cancer Recurrence in HCC
Vključevanje udeležencevFaza 4
- Rutgers New Jersey Medical School (New York), New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, New York
The Dragon PLC Trial (DRAGON-PLC)
Vključevanje udeležencev
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Vključevanje udeležencevFaza 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Študije za Rak jeter (hepatocelularni karcinom) v drugih mestih
- Houston, TX31 študij
- Dallas, TX19 študij
- Los Angeles, CA19 študij
- Boston, MA18 študij
- Cleveland, OH18 študij
- Chicago, IL16 študij
- Philadelphia, PA16 študij
- Pittsburgh, PA15 študij
- San Francisco, CA14 študij
- Orange, CA14 študij
- Jacksonville, FL14 študij
- San Antonio, TX13 študij
Druge študije v New York City
- Rak dojke136 študij
- Nemalicelični pljučni rak121 študij
- Rak (vse vrste)109 študij
- Rak prostate103 študij
- Metastatski rak93 študij
- Kolorektalni rak78 študij
- Rak jajčnikov69 študij
- Rak pljuč60 študij
- Množni mielom60 študij
- Rak trebušne slinavke60 študij
- Rak endometrija52 študij
- Akutna mieločna levkemija51 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.